ArticleScientific reports2026
Light-assisted drying enables vaccine stabilization and supports cold-chain-independent distribution.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Vaccination against infectious disease is one of the most significant advances in modern medicine. However, the thermal sensitivity of most vaccines necessitates distribution and storage at refrigerated or freezing temperatures. A lack of access to cold chain logistics remains one of the leading causes of under-vaccination worldwide. This study introduces a new technique, light-assisted drying (LAD), to create a protective amorphous trehalose matrix that preserves embedded biologics like vaccines during room-temperature storage. Biologics are suspended in a sugar solution and irradiated with a 1064 nm laser, which drives rapid evaporation of water and forms the protective amorphous matrix. In this study, LAD was applied to clinically relevant vaccines for the first time: 4CMenB, a multicomponent, aluminum-adjuvanted recombinant vaccine targeting Neisseria meningitidis serogroup B and inactivated poliovirus vaccine (IPV), a whole-virus inactivated formulation. Polarized light imaging confirmed that LAD processing produced an amorphous matrix without crystallization. For 4CMenB, ELISA showed that antigenicity was retained post-LAD and transmission electron microscopy (TEM) verified preservation of outer membrane vesicles and aluminum adjuvant nanostructures. An in vivo mouse study using LAD-processed 4CMenB showed a robust humoral immune response, confirming preserved immunogenicity. For IPV, ELISA demonstrated preserved antigenicity, and TEM confirmed structural integrity of the viral capsid. These findings demonstrate the potential of LAD to improve vaccine stability and support broader immunization efforts by reducing dependence on cold chain logistics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.